Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FCR immuno-chemotherapy for symptomatic Waldenstrom's macroglobulinemia
2005-000174-52Phase 2Completed
- Sponsor
- Associazione Malattie del Sangue
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine and cyclophosphamide in Waldenström macroglobulinemia (WM), sponsored by Associazione Malattie del Sangue. Started Dec 2007; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2005-000174-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000174-52.